| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
28-O-β-D-Glucopyranosyl pomolic acid targets urokinase plasminogen activator (uPA), a serine protease that converts plasminogen to plasmin, thereby promoting fibrinolysis and extracellular matrix degradation. uPA is involved in various pathological processes including cancer invasion, metastasis, and tissue remodeling. By inhibiting uPA with an IC50 of 37.82 µM, 28-O-β-D-Glucopyranosyl pomolic acid reduces plasminogen activation and subsequent matrix degradation.
|
|---|---|
| ln Vitro |
In vitro, 28-O-β-D-Glucopyranosyl pomolic acid demonstrates inhibition of urokinase plasminogen activator (uPA) with an IC50 of 37.82 µM. The compound shows concentration-dependent inhibition of uPA activity in biochemical assays using purified enzyme preparations. The glucosylation at the 28-position enhances the compound's water solubility compared to its aglycone form. The compound's uPA inhibitory activity makes it a valuable tool for studying fibrinolysis and cancer metastasis.
|
| ln Vivo |
In vivo activity data for 28-O-β-D-Glucopyranosyl pomolic acid are limited, as the compound is primarily studied in vitro. Based on its uPA inhibitory mechanism, the compound is expected to reduce tumor invasion and metastasis in animal models. However, detailed efficacy studies in animal models have not been extensively reported. The compound's potential for in vivo applications requires further investigation.
|
| Enzyme Assay |
The in vitro enzyme inhibition assay for 28-O-β-D-Glucopyranosyl pomolic acid typically involves measuring uPA activity using a chromogenic or fluorogenic peptide substrate. Purified human uPA is incubated with varying concentrations of the compound (0.1-1000 µM) in assay buffer (e.g., Tris-HCl, pH 7.4) at 37°C for 30-60 minutes. The reaction is initiated by adding the substrate, and absorbance or fluorescence is measured. IC50 values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines expressing uPA are cultured and treated with 28-O-β-D-Glucopyranosyl pomolic acid at concentrations ranging from 1-100 µM for 24-72 hours. uPA activity is measured in cell lysates or conditioned media using activity assays. Cell invasion and migration are assessed using Transwell or wound healing assays. Cell viability is assessed using MTT or CCK-8 assays.
|
| Animal Protocol |
In vivo animal studies for 28-O-β-D-Glucopyranosyl pomolic acid have not been extensively reported. Based on the compound's mechanism as a uPA inhibitor, potential in vivo studies would involve administration to tumor-bearing mouse models via oral gavage, intraperitoneal injection, or intravenous injection at doses ranging from 1-50 mg/kg. Tumor growth, invasion, and metastasis would be assessed. uPA activity would be measured in tumor tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 28-O-β-D-Glucopyranosyl pomolic acid have not been fully characterized. The molecular weight is 634.84 g/mol and the molecular formula is C₃₆H₅₈O₉. The compound has enhanced water solubility compared to its aglycone form due to the glucosyl group at the 28-position. Detailed pharmacokinetic parameters such as bioavailability, half-life, and protein binding have not been reported.
|
| Toxicity/Toxicokinetics |
Toxicology data for 28-O-β-D-Glucopyranosyl pomolic acid are limited. As a natural triterpenoid glycoside, the compound is generally considered to have low toxicity. However, comprehensive toxicology studies have not been conducted. Standard toxicological endpoints including cell viability, genotoxicity, and organ toxicity should be evaluated. The compound is intended for research use only.
|
| References | |
| Additional Infomation |
28-O-β-D-glucopyranose ester has been reported in Sanguisorba officinalis, Piclampnia selovii, and other organisms with available data.
28-O-β-D-Glucopyranosyl pomolic acid is a triterpenoid glycoside and uPA inhibitor with an IC50 of 37.82 µM. The compound has enhanced water solubility due to glucosylation at the 28-position. It is a valuable research tool for studying fibrinolysis, cancer invasion, and metastasis. The compound is intended for research use only and is not approved for therapeutic applications. |
| Molecular Formula |
C36H58O9
|
|---|---|
| Molecular Weight |
634.84
|
| Exact Mass |
634.408
|
| CAS # |
83725-24-0
|
| PubChem CID |
76322845
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
726.6±60.0 °C at 760 mmHg
|
| Flash Point |
219.1±26.4 °C
|
| Vapour Pressure |
0.0±5.4 mmHg at 25°C
|
| Index of Refraction |
1.595
|
| LogP |
6.73
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
45
|
| Complexity |
1220
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C([C@]12CC[C@@H](C)[C@](O)(C)[C@H]1C1=CC[C@@H]3[C@]4(CC[C@H](O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@@]1(CC2)C)C)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1
|
| InChi Key |
RRIMLWHUVCZACL-HPUCWRFUSA-N
|
| InChi Code |
InChI=1S/C36H58O9/c1-19-10-15-36(30(42)45-29-27(41)26(40)25(39)21(18-37)44-29)17-16-33(5)20(28(36)35(19,7)43)8-9-23-32(4)13-12-24(38)31(2,3)22(32)11-14-34(23,33)6/h8,19,21-29,37-41,43H,9-18H2,1-7H3/t19-,21-,22+,23-,24+,25-,26+,27-,28-,29+,32+,33-,34-,35-,36+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-1,10-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5752 mL | 7.8760 mL | 15.7520 mL | |
| 5 mM | 0.3150 mL | 1.5752 mL | 3.1504 mL | |
| 10 mM | 0.1575 mL | 0.7876 mL | 1.5752 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
